Investment Overview

PRIME exits® and American Healthcare Capital are proud to exclusively present an opportunity to acquire a majority interest in a profitable, rapidly growing prosthetics and orthotics platform operating in the Southeastern United States. The Company provides custom prosthetic, orthotic, and advanced bionic solutions through a patient-centric, technology-enabled clinical model.

The business has demonstrated strong revenue growth, meaningful margin expansion, and scalable unit economics, positioning it as an attractive platform investment within a resilient healthcare sub-sector benefiting from long-term demographic and technological tailwinds.

Business Highlights

• Customized prosthetic and orthotic solutions, including advanced bionic and myoelectric systems

• High-touch clinical model focused on outcomes, mobility, and patient independence

• Strong brand recognition with a mission-driven, empathetic care philosophy

• Diversified referral base including physicians, rehabilitation centers, and healthcare providers

• Asset-light operating structure with scalable infrastructure

• Favorable industry dynamics driven by aging population and increased demand for mobility solutions

Financial Summary

Gross revenue increased meaningfully from $1.0 million in 2024 to $1.4 million in 2025, reflecting strong organic growth and improved operating scale. This momentum is expected to continue in 2026, with projected revenue of $1.75 million, representing a two-year compound growth profile that is both consistent and sustainable.

Adjusted EBITDA expanded at an even faster pace, rising from approximately $198,000 in 2024 (19%) to $405,000 in 2025 (29%). The improvement reflects both revenue growth and enhanced cost efficiency. For 2026, adjusted EBITDA is projected at $508,000, maintaining a 29% margin, which indicates that profitability gains are being preserved as the business scales rather than eroding with growth.

Key Financial Takeaways:

• ~39% revenue growth from 2024 to 2025

• Adjusted EBITDA more than doubled year-over-year

• Significant margin expansion driven by operating leverage

• Consistent profitability with clear visibility into continued growth

• Growth Opportunities

• Geographic expansion through de-novo locations and tuck-in acquisitions

• Increased penetration of higher-margin advanced prosthetic and bionic solutions

• Deeper referral relationships with hospitals, rehabilitation networks, and VA systems

• Institutional support to professionalize operations and accelerate scale

• Platform consolidation opportunity within a fragmented prosthetics & orthotics market

Key Valuation Drivers and Ideal Buyer Profile

The Company’s valuation is underpinned by strong historical growth, expanding margins, and a highly scalable operating model, further differentiated by its position as a veteran- and woman-owned healthcare platform in a resilient, growing sector.

A key value driver is the founders’ commitment to remain actively involved post-transaction and to roll over a meaningful equity stake, ensuring operational continuity and alignment with a partner’s growth objectives. A structured earn-out is also contemplated to bridge valuation expectations and directly link additional consideration to future performance, supporting a shared goal of scaling the business and achieving a targeted liquidity event in approximately five years.

The Company is well suited for healthcare-focused private equity firms, strategic prosthetics and orthotics platforms, family offices seeking scalable healthcare investments, and investors pursuing platform build-and-expand strategies.

Transaction Overview & Asking Price

Target Valuation: Founders are open to majority equity at fair market valuation from a strategic or a capital partner that can help them grow and scale to the next level, reflecting the Company’s strong growth trajectory, profitability, and future potential.

Transaction Structure: Majority recapitalization with seller rollover equity.

Consideration: Total consideration may include a combination of cash at closing, rollover equity, and a performance-based earn-out tied to future growth.

Exclusions: Cash, working capital, accounts receivable, and real property.